The RAS (KRAS, NRAS, HRAS)-RAF (ARAF, BRAF, RAF1)-MEK (MAP2K1/2)-ERK (MAPK1/3) pathway is altered in ~40% of all human cancers, mainly through oncogenic mutations in RAS (32%) and the downstream effector BRAF (~10%). The gene discussed is RAF1; the disease is cancer.